ALNY vs REGN
Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, both Healthcare
Regeneron Pharmaceuticals is the larger company at $64B against $39B. On trailing earnings REGN is the cheaper of the two at a P/E of 18.4 against 118.1, a gap that is only a bargain if the two are growing at similar rates. Over the past year REGN returned +25% against -49% for ALNY. The RyuScore puts REGN ahead, 70 against 15 out of 100.
| Figure | ALNY | REGN |
|---|---|---|
| Last close | $233 | $746 |
| Market cap | $39B | $64B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 118.1 | 18.4 |
| 1-year return | -49% | +25% |
| 5-year return | +24% | +18% |
| RyuScoresector-relative, 1–10 | 15/100 | 70/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alnylam Pharmaceuticals, Inc.
Revenue of $2.5B in H1 2026, net income $370M. Its largest reported line is Amvuttra, 67% of the disclosed total.
Regeneron Pharmaceuticals
Revenue of $4.3B in Q2 2026, net income $1.3B. Its largest reported line is Share Of Profit Losses, 50% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.